Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

por Rosaria De Filippi, Fortunato Morabito, Armando Santoro, Giovanni Tripepi, Francesco D’Alò, Luigi Rigacci, Francesca Ricci, Emanuela Morelli, Pier Luigi Zinzani, Antonio Pinto
Publicado 2021